Abbott has announced it has received FDA clearance for its XIENCE Xpedition everolimus eluting coronary stent system, according to a news release.
According to Abbott, the XIENCE Xpedition features a new stent delivery system designed to improve deliverability, particularly in challenging coronary anatomies.
"The launch of XIENCE Xpedition in the United States will advance Abbott's worldwide market-leading position in drug eluting stents," said John M. Capek, PhD, executive vice president of Medical Devices for Abbott, in the release. "XIENCE Xpedition leverages the strong clinical outcomes of XIENCE V and XIENCE PRIME while providing important advantages in deliverability. With its redesigned stent delivery system and a full matrix of sizes, XIENCE Xpedition provides physicians with a comprehensive, trusted option to treat a broad range of patients with coronary artery disease."
XIENCE Xpedition has diameters ranging from 2.25 mm to 4 mm and lengths from 8 mm to 38 mm.
Abbott is headquartered in Abbott Park, Ill.
Related Articles on FDA Clearances:
Alphatec Spine Receives FDA Clearance for Anterior Cervical Interbody Device and MIS System
Dune Medical Receives FDA Clearance for MarginProbe Breast Cancer Surgery System
Medical Modeling Receives FDA Clearance for Virtual Surgical Planning System